JP2023179414A5 - - Google Patents

Info

Publication number
JP2023179414A5
JP2023179414A5 JP2023135227A JP2023135227A JP2023179414A5 JP 2023179414 A5 JP2023179414 A5 JP 2023179414A5 JP 2023135227 A JP2023135227 A JP 2023135227A JP 2023135227 A JP2023135227 A JP 2023135227A JP 2023179414 A5 JP2023179414 A5 JP 2023179414A5
Authority
JP
Japan
Prior art keywords
composition
apheresis
subject
raav vector
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023135227A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023179414A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/042553 external-priority patent/WO2019018439A1/en
Application filed filed Critical
Publication of JP2023179414A publication Critical patent/JP2023179414A/ja
Publication of JP2023179414A5 publication Critical patent/JP2023179414A5/ja
Pending legal-status Critical Current

Links

JP2023135227A 2017-07-17 2023-08-23 アフェレーシスの方法及び使用 Pending JP2023179414A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762533579P 2017-07-17 2017-07-17
US62/533,579 2017-07-17
PCT/US2018/042553 WO2019018439A1 (en) 2017-07-17 2018-07-17 APHERESE METHODS AND ASSOCIATED USES
JP2020502112A JP2020530834A (ja) 2017-07-17 2018-07-17 アフェレーシスの方法及び使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020502112A Division JP2020530834A (ja) 2017-07-17 2018-07-17 アフェレーシスの方法及び使用

Publications (2)

Publication Number Publication Date
JP2023179414A JP2023179414A (ja) 2023-12-19
JP2023179414A5 true JP2023179414A5 (https=) 2026-02-24

Family

ID=65016674

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020502112A Pending JP2020530834A (ja) 2017-07-17 2018-07-17 アフェレーシスの方法及び使用
JP2023135227A Pending JP2023179414A (ja) 2017-07-17 2023-08-23 アフェレーシスの方法及び使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020502112A Pending JP2020530834A (ja) 2017-07-17 2018-07-17 アフェレーシスの方法及び使用

Country Status (9)

Country Link
US (1) US20200164008A1 (https=)
EP (1) EP3655001A4 (https=)
JP (2) JP2020530834A (https=)
CN (1) CN111225677A (https=)
AU (1) AU2018304194B2 (https=)
BR (1) BR112020000995A2 (https=)
CA (1) CA3069880A1 (https=)
MX (1) MX2020000713A (https=)
WO (1) WO2019018439A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3384035A4 (en) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
MY208145A (en) 2018-06-18 2025-04-18 Res Inst Nationwide Childrens Hospital Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
KR20220133969A (ko) 2020-01-28 2022-10-05 프리라인 테라퓨틱스 리미티드 바이러스 벡터에 대한 중화 항체 역가를 결정하기 위한 개선된 분석법
IL299094A (en) * 2020-06-15 2023-02-01 Res Inst Nationwide Childrens Hospital Administration of an adeno-associated virus vector for muscular dystrophies
CN111500635B (zh) * 2020-07-02 2020-10-09 北京大学第三医院（北京大学第三临床医学院） 一种包含携带核酸分子的载体的试剂盒
RU2020122141A (ru) * 2020-07-03 2022-01-04 Максим Петрович Никитин Способ и композиция на основе генотерапевтического агента и антитела, связывающегося с клетками крови
CN116547008A (zh) 2020-09-23 2023-08-04 艾柏力维亚生技有限公司 用于增加病毒载体的效力的化合物
US12071633B2 (en) 2020-10-13 2024-08-27 Kriya Therapeutics, Inc. Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
AU2022363635A1 (en) * 2021-10-16 2024-03-21 Eliaz Therapeutics, Inc. Apheresis of whole blood
US20250213707A1 (en) 2022-03-24 2025-07-03 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses
WO2026028158A1 (en) * 2024-07-31 2026-02-05 Biohaven Therapeutics Ltd. Targeted degradation of anti-aav antibodies to enable aav-based gene therapy

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU691297B2 (en) * 1994-05-13 1998-05-14 Miltenyi Biotec Gmbh Sterile and pyrogen-free columns coupled to protein for binding and removal of substances from blood
US6406861B1 (en) * 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
EP1315551B1 (en) * 1999-06-03 2015-11-04 Advanced Extravascular Systems One step removal of unwanted molecules from circulating blood
US6464976B1 (en) * 1999-09-07 2002-10-15 Canji, Inc. Methods and compositions for reducing immune response
US6379708B1 (en) * 1999-11-20 2002-04-30 Cytologic, Llc Method for enhancing immune responses in mammals
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
JP2010131033A (ja) * 2007-03-16 2010-06-17 Medical Science Co Ltd 医療用吸着剤
US8123713B2 (en) * 2008-08-12 2012-02-28 Caridian Bct, Inc. System and method for collecting plasma protein fractions from separated blood components
US9546112B2 (en) * 2010-03-22 2017-01-17 Association Institut De Myologie Methods of increasing efficiency of vector penetration of target tissue
US20130068691A1 (en) * 2011-08-05 2013-03-21 Henry John Smith Targeted apheresis for the treatment of rheumatoid arthritis and immune disorders
ES2857773T5 (es) * 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
SE1200356A1 (sv) * 2011-10-30 2013-05-01 Kurt Nilsson Polymerbaserad produkt och användning
US9434928B2 (en) * 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
US9717841B2 (en) * 2012-09-11 2017-08-01 Gary L. McNeil Closed-circuit device and methods for isolation, modification, and re-administration of specific constituents from a biological fluid source
IL297919A (en) * 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
EP3204503A1 (en) * 2014-10-06 2017-08-16 Arthrogen BV Aav-based gene therapy
EP3054007A1 (en) * 2015-02-09 2016-08-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step
US20180093032A1 (en) * 2016-08-15 2018-04-05 Henry John Smith Targeted apheresis using binding agents or ligands immobilized on membranes
JP7610923B2 (ja) * 2016-09-02 2025-01-09 スパーク セラピューティクス インコーポレイテッド Ｃｎｓ障害を治療するための方法及びベクター
WO2018109207A1 (en) * 2016-12-16 2018-06-21 Uniqure Ip B.V. Immunoadsorption
WO2018158397A1 (en) * 2017-03-02 2018-09-07 Genethon Method for removing anti-aav antibodies from a blood-derived composition
WO2019094253A1 (en) * 2017-11-08 2019-05-16 Avexis Inc. Means and method for preparing viral vectors and uses of same

Similar Documents

Publication Publication Date Title
JP2023179414A5 (https=)
Konno et al. Efficient whole brain transduction by systemic infusion of minimally purified AAV-PHP. eB
Liu et al. Crossing the blood-brain barrier with AAV vectors
AU2023200175B2 (en) Recombinant Adeno-Associated Virus Delivery Of Exon 2-Targeted U7snRNA Polynucleotide Constructs
JP6991095B2 (ja) ウイルスベクター精製における拡張可能な製造プラットフォームおよび遺伝子治療における使用のための高純度ウイルスベクター
Daya et al. Gene therapy using adeno-associated virus vectors
JP2020533959A5 (https=)
EP3039146B1 (en) Products and methods for treatment of amyotrophic lateral sclerosis
AU2018304194B2 (en) Apheresis methods and uses
AU2023217698A1 (en) Aav capsid variants and uses thereof
CA3061365A1 (en) Modulatory polynucleotides
GB2574243A (en) Adeno-associated viral vector-mediated gene therapy for treating fragile X-associated disorders
KR20210148273A (ko) 근육 발현을 위한 하이브리드 프로모터
CA3259902A1 (en) AAV Capsid Variants and Their Uses
US20250388626A1 (en) Aav capsid variants and uses thereof
WO2025038430A1 (en) Aav capsid variants and uses thereof
Benchaouir et al. Gene and splicing therapies for neuromuscular diseases
Sorroza-Martinez et al. Recent Advances in Therapeutics and Manufacturing Processes of Recombinant Adeno-Associated Virus for the Treatment of Lung Diseases
JP2022531892A5 (https=)
Morgenstern et al. Adeno-associated viral gene delivery in neurodegenerative disease
Henriques et al. Isolation of biologically active extracellular vesicles-associated AAVs for gene delivery to the brain by size exclusion chromatography
de Almeida et al. Isolation of Biologically Active Extracellular Vesicles-Associated AAVs for Gene Delivery to the Brain by Size Exclusion Chromatography
HK40098369A (en) Products and methods for treatment of amyotrophic lateral sclerosis
AU2023306319A1 (en) Adeno-associated virus gene therapy products and methods
Van der Perren et al. Using recombinant adeno-associated viral vectors for gene expression in the brain